Oncogenes and effector targets
In lung cancer and in intestinal-tract tumors such as pancreatic cancer, bowel cancer and cholangiocarcinoma, KRAS is the most widely mutated gene and an undoubted therapeutic target. Nevertheless, KRAS continues to be refractory to targeted therapies and its inhibition is thus an unmet clinical need. Therefore, our group focuses on the identification of new molecular targets in KRAS-dependent tumors and on the discovery of innovative therapeutic strategies for these tumors.
Our studies are based on a multimodal approach, which includes functional genomic techniques, mouse genetics, in vitro and xenograft models, analysis of human cancer samples, and clinical parameters. Furthermore, the laboratory recently incorporated work with organoids (3-D organ buds) from primary human and murine cells, and from cell lines. This model makes it possible to carry out in vitro and in vivo studies of gene modulation, pharmacological treatments and cell co-cultures.
To date, we have carried out innovative computational analyses by integrating databases of patients with lung cancer and pancreatic cancer in which KRAS is mutated to unveil new critical elements in these tumors. Furthermore, we have characterized their functional and clinical role in close collaboration with professionals from the Clínica Universidad de Navarra who have an interest in lung and intestinal-tract tumors.
The group is associated with CIBERonc (CB16/12/00443) and the European Network for the Study of Cholangiocarcinoma (European Network for the Study of Cholangiocarcinoma -ENSCCA-).
Fecha de actualización: Noviembre 2018
"We are very interested in identifying new molecular targets in KRAS-dependent tumors and in discovering innovative therapeutic strategies for treating these tumors", Dr. Silve Vicent.